Thursday, Mar 4 2021 | Time 21:19 Hrs(IST)
image
  • Assam to promote students from class 1 to 9 without examination
  • NASSCOM launches Deep Tech Club 2 0
  • Assam: Congress promises to give 5 lakh jobs to people
  • Familiar foes Goa and Mumbai City collide in playoff curtain-raiser
  • Jharkhand Budget Session: BJP MLAs create uproar over illegal mining
  • Headmaster arrested in bribery case in Aurangabad
  • Food prices up, oil and sugar at multi-year highs in Feb: FAO
  • WTT Contender: Indian challenge ends as Sharath Kamal bows out
  • WTT Contender: Indian challenge ends as Sharath Kamal bows out
  • Shivraj Chouhan receives first jab of COVID-19 vaccine
  • Bihar Govt announces separate department for skill and entrepreneurship
  • AP CM directs officials to expedite construction of Anganwadi centres
  • Jharkhand: Jilted CRPF jawan attacks nine family members of alleged girlfriend, 4 serious
  • ED files prosecution complaint against Himachal based company in a fraud case
  • Vigilance bureau registers enquiry to expose malpractices in records of food items samples
Business EconomyPosted at: Jan 27 2021 9:52PM


GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine

Kolkata, Jan 27 (UNI) GSK, PATH, and Bharat Biotech (BBIL) today announced the signing of a product transfer agreement for the malaria vaccine, RTS,S/AS01E 1 . The agreement includes the transfer of manufacturing of the RTS,S antigen part of the vaccine and the grant of a license on all rights pertaining to the RTS,S/AS01 malaria vaccine to BBIL. GSK will retain the production of the adjuvant of the vaccine (AS01E) and will supply it to BBIL.

BBIL is an established, innovative biotechnology company based in Hyderabad, India, focused on delivering safe, affordable, and high-quality vaccines and bio-therapeutics against infectious diseases. The agreement recognises the track record and expertise of BBIL in developing and supplying vaccines against infectious diseases, including as an established supplier of global health vaccines to Gavi, the Vaccine Alliance, and to UNICEF. BBIL was selected through a comprehensive, competitive process undertaken by GSK and PATH, working in consultation with the World Health Organization (WHO).

The RTS,S/AS01E malaria vaccine, developed by GSK for more than 30 years, and in partnership with PATH since 2001, is currently being piloted in regions of Ghana, Kenya, and Malawi under the Malaria Vaccine Implementation Programme (MVIP). Ministries of health are leading the implementation of the vaccine, which is being given to young children through the three countries’ routine immunisation programmes, with WHO providing technical and scientific leadership, playing a coordinating role, and working in collaboration with GSK, PATH, and a range of other partners.

RTS,S/AS01E is the first, and to date, the only malaria vaccine to have received a positive review by regulatory authorities (positive scientific opinion from the European Medicines Agency and approval by the regulatory authorities of Ghana, Kenya, and Malawi for use in the MVIP). The first dose of the vaccine has reached more than 500,000 children since the pilots were initiated by ministries of health in the three participating countries in 2019.

This agreement with BBIL is the result of efforts by GSK, PATH, and WHO to help ensure long-term sustainable vaccine supply, in the event of a WHO policy recommendation for broader use and a commitment of sustained funding. This builds on existing GSK commitments to donate up to 10 million RTS,S/AS01E doses for use in the pilot, and to supply up to 15 million doses annually until 2028 if the product is recommended for wider use by WHO. It is expected that by 2029, at the latest, BBIL will be the sole supplier of the vaccine, with GSK supplying the adjuvant AS01E to them.

The timing of the new agreement will help ensure the maintenance of long-term vaccine supply, given the time required for a successful technology transfer. GSK has strong expertise in transferring vaccine manufacturing technologies to partners, with more than 20 technology transfers currently ongoing. This expertise, with support from BBIL and PATH, will now be applied to deliver a successful transfer of production of the RTS,S antigen to BBIL.

Thomas Breuer, GSK Vaccines Chief Medical Officer and Vaccines Global Health lead said: “Our 30- year and ongoing commitment to RTS,S/AS01E represents significant leadership and investment in global health vaccines, but also a huge scientific achievement in the fight against malaria. With a child still dying of malaria every two minutes, helping secure the long-term future of the only vaccine available by working with an established leader like Bharat Biotech is vital for the continued fight against this devastating disease. GSK is delighted to sign this agreement with Bharat Biotech”.

John Bawa, Africa Lead, Vaccine Implementation, PATH, said: “Malaria takes such a toll on African children, our health care systems, and our economies, that having this vaccine is cause for optimism, given its potential to further reduce malaria illnesses and deaths. Thanks to the pilot programme, children in some of the areas hardest hit by malaria—here in Ghana, and in Kenya and Malawi—have been receiving this vaccine through routine immunisation programmes for more than one year. We at PATH are proud to be a part of this remarkable effort—together with partners across Africa, GSK, and WHO—to get to this point. Now, with the signing of this agreement with Bharat Biotech, we have an additional, new partner to help ensure that this vaccine can be more widely available for use in Africa, alongside other malaria interventions, in the years to come”.

Krishna M. Ella, Bharat Biotech, Chairman & Managing Director said: “We salute the commitment by GSK, PATH, and partners, in developing a novel vaccine against malaria, a dreaded disease with more than 200 million cases worldwide. We are truly honoured to support this partnership and to provide global access to RTS,S/AS01E. With prior expertise in malaria research, WHO prequalified vaccines, supplied to more than 70 countries, Bharat Biotech is geared up for large-scale manufacturing, and to provide continuous long-term supply of this life-saving vaccine”.

UNI XC-AND
Please log in to get detailed story.
Tags: #GSK# PATH# and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS#S/AS01E malaria vaccine
More News

NASSCOM launches Deep Tech Club 2 0

04 Mar 2021 | 8:39 PM

Kolkata, Mar 4 (UNI) In an effort to boost India’s tech start-up ecosystem, the National Association
of Software and Services Companies (NASSCOM), on Thursday announced Deep Tech Club (DTC) 2.0; the second edition for its DeepTech Mentoring program, an initiative to nurture and promote
Indian DeepTech products solving global problems.

see more..

Tata Motors launches the Tiago XTA

04 Mar 2021 | 8:37 PM

Kolkata, Mar 04 (UNI) Tata Motors today announced the launch of the new XTA variant of its successful hatchback – the Tata Tiago, at a starting price of INR 5.99 Lakhs (Ex. Showroom Delhi).

see more..

Paytm Money becomes India's growth enabler for wealth products, aims at 10 million users & 75 million yearly transactions in FY'22

04 Mar 2021 | 8:36 PM

Kolkata, Mar 04 (UNI) India’s homegrown digital financial services platform Paytm, today announced that its wholly-owned subsidiary 'Paytm Money' is targeting over 10 million users and 75 million yearly transactions in FY'22.

see more..

Maruti Suzuki Vitara Brezza becomes India’s fastest selling compact SUV to clock 6 lac sales; achieves feat within 5 years of launch

04 Mar 2021 | 8:12 PM

Gurugram, Mar 04 (UNI) India’s best-selling compact SUV, Maruti Suzuki Vitara Brezza, sets yet another remarkable milestone, clocks 6 Lakh sales within a short time span of 5 years. Since its launch in 2016, Vitara Brezza has been the undisputed market leader in the compact SUV segment with its enhanced sportiness, bolder SUV looks, stronger stance, premium interiors and host of features. Its dominance over the segment is evident from the fact that it has not only emerged as the fastest selling compact SUV in the country, but also the most awarded compact SUV.

see more..

DSP Investment Managers launches DSP Floater Fund

04 Mar 2021 | 8:00 PM

Kolkata, Mar 04 (UNI) DSP Investment Managers Private Limited has announced the launch of DSP Floater Fund (the scheme), an open ended debt scheme predominantly investing in sovereign bonds and overnight index swaps (OIS) to help investors better navigate interest rate cycles.

see more..
image